Business Wire

VA-FLIR-SYSTEMS-INC

15.10.2020 16:04:10 CEST | Business Wire | Press release

Share
FLIR Receives Additional $26M Contract for U.S. Army’s Nuclear, Biological and Chemical Reconnaissance Vehicle Program

FLIR Systems, Inc. (NASDAQ: FLIR) announced it has been awarded a $26 million contract modification in support of the Nuclear, Biological and Chemical Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU) program for the U.S. Army. The Other Transaction Authority (OTA) agreement was awarded through the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) as a follow-on to a $48 million contract announced in April 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005675/en/

FLIR is the lead integrator in modernizing the Army’s NBCRV system with improved and autonomous CBRN sensors. Earlier this year, the company delivered initial prototypes of the NBCRV SSU system for a focused assessment at Fort Bliss, Texas. Soldiers employed the FLIR prototype in realistic battlefield scenarios to sense and rapidly avoid CBRN hazards. The new contract allows FLIR to continue developing the Sensor Suite and to deliver mature prototypes for government testing in 2021.

Among other third-party solutions, the NBCRV Sensor Suite will feature capabilities of the FLIR R80D SkyRaider™ drone integrated with a specialized version of the FLIR IBAC bio-detection sensor. This next phase also will pair the NBCRV with a ground robotic vehicle to expand the system’s use with manned-unmanned teams. A FLIR-developed command and control system will bring together all devices and platforms with sensor fusion and automation features that lessen the cognitive burden on users and improve decision-making.

“Our ability to build and integrate manned and unmanned sensing solutions across a wide threat space is where FLIR differentiates itself,” said Vice President and General Manager of the Unmanned Systems & Integrated Solutions business at FLIR, Roger Wells. “Incorporating UAV and UGV platforms into NBCRV aligns with our efforts to develop full sensing capabilities that can act as force multipliers and boost mission success for our troops.

“Whether through air- or ground-based detection systems, FLIR is uniquely positioned in the defense industry with deep expertise in both intelligent sensor and autonomous systems technology that keeps warfighters safe,” Wells added.

FLIR is supporting other efforts by JPEO-CBRND. In the past year, the company has won two contracts worth more than $55 million to field its FLIR Agentase™ C2 chemical warfare disclosure spray, formulated to detect nerve agents like VX and sarin as well as blister agents such as sulfur mustard.

Work on the NBCRV program has begun and is expected to continue through 2022 at FLIR facilities in West Lafayette, Indiana; Stillwater, Oklahoma; and Elkridge, Maryland. For more on FLIR System’s integrated solutions for government and defense, visit www.flir.com/integrated-solutions . For more on FLIR’s chemical, biological, radiological, nuclear, and explosive detection technologies, visit www.flir.com/threat-detection .

About FLIR Systems, Inc.

Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense,” creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir .

Forward Looking Statements

The statements in this release by Roger Wells and the other statements in this release about the contract and order described above are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates, and projections about FLIR's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including the following: the ability to manufacture and deliver the systems referenced in this release, changes in pricing of FLIR's products, changing demand for FLIR's products, product mix, the impact of competitive products and pricing, constraints on supplies of critical components, excess or shortage of production capacity, the ability of FLIR to manufacture and ship products in a timely manner, FLIR's continuing compliance with U.S. export control laws and regulations, and other risks discussed from time to time in FLIR's Securities and Exchange Commission filings and reports. In addition, such statements could be affected by general industry and market conditions and growth rates, and general domestic and international economic conditions. Such forward-looking statements speak only as of the date on which they are made and FLIR does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release, or for changes made to this document by wire services or Internet service providers.

Social Media:

https://www.facebook.com/FLIR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release

Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release

Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath

De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release

The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par

Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release

Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr

Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press release

Southern California-Based Company has developed a disruptive biosensor for integration into next-generation screening and diagnostic devices Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye